NFKB1 and atherosclerosis: PCSK9i including inclisiran, evolocumab, and alirocumab lower LDL cholesterol, slow atherosclerosis progression, reduce major adverse cardiovascular events, and diminish inflammatory markers by promoting LDL receptor recycling and modulating anti-inflammatory pathways such as NF-κB and IL-6, effectively blocking PCSK9-mediated degradation of LDL receptors to enhance LDL clearance and reduce vascular inflammation [206].